

Steven A Julious

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7141846/publications.pdf>

Version: 2024-02-01

110
papers

8,379
citations

136885

32
h-index

51562

86
g-index

146
all docs

146
docs citations

146
times ranked

13840
citing authors

#	ARTICLE	IF	CITATIONS
1	Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. <i>Medical Decision Making</i> , 2022, 42, 461-473.	1.2	4
2	Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequence. <i>Pharmaceutical Statistics</i> , 2022, 21, 460-475.	0.7	4
3	Practical guide to sample size calculations: Installation of the app <scp>SampSize</scp>. <i>Pharmaceutical Statistics</i> , 2022, , .	0.7	0
4	Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation. <i>Clinical Rehabilitation</i> , 2021, 35, 703-717.	1.0	9
5	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 93-104.	1.1	32
6	Sample sizes for cluster-randomised trials with continuous outcomes: Accounting for uncertainty in a single intra-cluster correlation estimate. <i>Statistical Methods in Medical Research</i> , 2021, 30, 2459-2470.	0.7	6
7	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. <i>PLoS ONE</i> , 2021, 16, e0258689.	1.1	2
8	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>Trials</i> , 2020, 21, 528.	0.7	10
9	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>BMJ</i> , The, 2020, 369, m115.	3.0	57
10	How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. <i>Trials</i> , 2020, 21, 252.	0.7	4
11	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	24
12	Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 821-833.	4.9	116
13	Progression criteria in trials with an internal pilot: an audit of publicly funded randomised controlled trials. <i>Trials</i> , 2019, 20, 493.	0.7	28
14	A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. <i>Value in Health</i> , 2019, 22, 391-398.	0.1	18
15	Calculation of confidence intervals for a finite population size. <i>Pharmaceutical Statistics</i> , 2019, 18, 115-122.	0.7	4
16	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. <i>Health Technology Assessment</i> , 2019, 23, 1-88.	1.3	15
17	Are pilot trials useful for predicting randomisation and attrition rates in definitive studies: A review of publicly funded trials. <i>Clinical Trials</i> , 2018, 15, 189-196.	0.7	34
18	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. <i>BMC Medicine</i> , 2018, 16, 210.	2.3	28

#	ARTICLE	IF	CITATIONS
19	DELTA ² guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2018, 363, k3750.	2.4	90
20	DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. <i>Trials</i> , 2018, 19, 606.	0.7	50
21	Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial – the development of the DELTA2 guidance. <i>Trials</i> , 2018, 19, 542.	0.7	7
22	Multicentre, double-blind, crossover trial to identify the Optimal Pathway for Treating neuropathic pain in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 578.	0.7	12
23	At-risk children with asthma (ARC): a systematic review. <i>Thorax</i> , 2018, 73, 813-824.	2.7	87
24	Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. <i>Clinical Epidemiology</i> , 2018, Volume 10, 153-157.	1.5	137
25	Open-label, cluster randomised controlled trial and economic evaluation of a brief letter from a GP on unscheduled medical contacts associated with the start of the school year: the PLEASANT trial. <i>BMJ Open</i> , 2018, 8, e017367.	0.8	2
26	Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5–12 years. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 16088.	1.1	1
27	Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study. <i>Pharmacoeconomics</i> , 2017, 35, 561-573.	1.7	13
28	Corrections: The disagreeable behaviour of the kappa statistic. <i>Pharmaceutical Statistics</i> , 2017, 16, 95-95.	0.7	0
29	Can emergency medicine research benefit from adaptive design clinical trials?. <i>Emergency Medicine Journal</i> , 2017, 34, 243-248.	0.4	4
30	Choosing the target difference (effect size™) for a randomised controlled trial - DELTA2 guidance protocol. <i>Trials</i> , 2017, 18, 271.	0.7	10
31	Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. <i>BMJ Open</i> , 2017, 7, e015276.	0.8	335
32	Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity. <i>BMC Medical Research Methodology</i> , 2017, 17, 149.	1.4	6
33	PPI in the PLEASANT trial: involving children with asthma and their parents in designing an intervention for a randomised controlled trial based within primary care. <i>Primary Health Care Research and Development</i> , 2016, 17, 536-548.	0.5	12
34	Automated telephone communication systems for preventive healthcare and management of long-term conditions. <i>The Cochrane Library</i> , 2016, 2016, CD009921.	1.5	83
35	Practical guide to sample size calculations: an introduction. <i>Pharmaceutical Statistics</i> , 2016, 15, 68-74.	0.7	34
36	Practical guide to sample size calculations: non-inferiority and equivalence trials. <i>Pharmaceutical Statistics</i> , 2016, 15, 80-89.	0.7	74

#	ARTICLE	IF	CITATIONS
37	Practical guide to sample size calculations: superiority trials. <i>Pharmaceutical Statistics</i> , 2016, 15, 75-79.	0.7	14
38	Adaptive designs undertaken in clinical research: a review of registered clinical trials. <i>Trials</i> , 2016, 17, 150.	0.7	66
39	Pilot Studies in clinical research. <i>Statistical Methods in Medical Research</i> , 2016, 25, 995-996.	0.7	14
40	Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1057-1073.	0.7	903
41	Understanding Variation in Sets of N-of-1 Trials. <i>PLoS ONE</i> , 2016, 11, e0167167.	1.1	59
42	Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. <i>Trials</i> , 2015, 16, 585.	0.7	14
43	Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. <i>Trials</i> , 2015, 16, 430.	0.7	31
44	A theory-based online health behaviour intervention for new university students (U@Uni:LifeGuide): results from a repeat randomized controlled trial. <i>Trials</i> , 2015, 16, 555.	0.7	51
45	The disagreeable behaviour of the kappa statistic. <i>Pharmaceutical Statistics</i> , 2015, 14, 74-78.	0.7	47
46	Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 18.	0.7	37
47	NOURISH, Nutritional Outcomes from a Randomised Investigation of Intradialytic oral nutritional Supplements in patients receiving Haemodialysis: a pilot randomised controlled trial. <i>Pilot and Feasibility Studies</i> , 2015, 1, 11.	0.5	7
48	An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0141104.	1.1	31
49	The analysis of the use of "unascertained"™ for sudden unexpected deaths in infancy from 1988 to 2010. <i>Archives of Disease in Childhood</i> , 2014, 99, 300-301.	1.0	0
50	Estimating effect sizes for health-related quality of life outcomes. <i>Statistical Methods in Medical Research</i> , 2014, 23, 430-439.	0.7	9
51	Reducing waste from incomplete or unusable reports of biomedical research. <i>Lancet</i> , The, 2014, 383, 267-276.	6.3	982
52	A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trial. <i>BMC Public Health</i> , 2014, 14, 563.	1.2	71
53	The statistical interpretation of pilot trials: should significance thresholds be reconsidered?. <i>BMC Medical Research Methodology</i> , 2014, 14, 41.	1.4	266
54	An investigation of the impact of futility analysis in publicly funded trials. <i>Trials</i> , 2014, 15, 61.	0.7	16

#	ARTICLE	IF	CITATIONS
55	A survey of birth order status of students studying for medical degree at the University of Sheffield. <i>JRSM Open</i> , 2014, 5, 205427041453332.	0.2	1
56	A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. <i>Trials</i> , 2013, 14, 166.	0.7	295
57	A theory-based online health behavior intervention for new university students: study protocol. <i>BMC Public Health</i> , 2013, 13, 107.	1.2	23
58	Nutritional outcomes from a randomised investigation of intradialytic oral nutritional supplements in patients receiving haemodialysis, (NOURISH): a protocol for a pilot randomised controlled trial. <i>SpringerPlus</i> , 2013, 2, 515.	1.2	3
59	An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. <i>BMC Medical Research Methodology</i> , 2013, 13, 104.	1.4	523
60	Meta-analysis in clinical research. <i>Statistical Methods in Medical Research</i> , 2013, 22, 115-116.	0.7	0
61	Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients. <i>Statistical Methods in Medical Research</i> , 2013, 22, 190-218.	0.7	18
62	Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): study protocol for a cluster randomised control trial. <i>Trials</i> , 2013, 14, 297.	0.7	17
63	Environmental triggers of hospital admissions for school-age children with asthma in two British cities: Figure 1. <i>Emergency Medicine Journal</i> , 2012, 29, 844-845.	0.4	1
64	Computer Therapy Compared With Usual Care for People With Long-Standing Aphasia Poststroke. <i>Stroke</i> , 2012, 43, 1904-1911.	1.0	119
65	Influence of Adaptive Analysis on Unnecessary Patient Recruitment: Reanalysis of the RATPAC Trial. <i>Annals of Emergency Medicine</i> , 2012, 60, 442-448.e1.	0.3	5
66	Seven useful designs. <i>Pharmaceutical Statistics</i> , 2012, 11, 24-31.	0.7	4
67	Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis. <i>Pharmaceutical Statistics</i> , 2012, 11, 49-56.	0.7	7
68	Sample sizes for trials involving multiple correlated multiple comparisons. <i>Pharmaceutical Statistics</i> , 2012, 11, 177-185.	0.7	21
69	Tutorial in biostatistics: sample sizes for parallel group clinical trials with binary data. <i>Statistics in Medicine</i> , 2012, 31, 2904-2936.	0.8	40
70	A comparison of methods for sample size estimation for non-inferiority studies with binary outcomes. <i>Statistical Methods in Medical Research</i> , 2011, 20, 595-612.	0.7	22
71	Seasonality of medical contacts in school-aged children with asthma: Association with school holidays. <i>Public Health</i> , 2011, 125, 769-776.	1.4	23
72	Rehabilitation of older patients: day hospital compared with rehabilitation at home. <i>Clinical Outcomes. Age and Ageing</i> , 2011, 40, 557-562.	0.7	16

#	ARTICLE	IF	CITATIONS
73	Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. <i>Pharmaceutical Statistics</i> , 2011, 10, 70-73.	0.7	16
74	The potential for bias in reporting of industry-sponsored clinical trials. <i>Pharmaceutical Statistics</i> , 2011, 10, 74-79.	0.7	16
75	Making available information from studies sponsored by the pharmaceutical industry: some current practices. <i>Pharmaceutical Statistics</i> , 2011, 10, 60-69.	0.7	7
76	The ABC of non-inferiority margin setting from indirect comparisons. <i>Pharmaceutical Statistics</i> , 2011, 10, 448-453.	0.7	15
77	Time to end the non-inferiority complex?. <i>Pharmaceutical Statistics</i> , 2011, 10, 393-394.	0.7	1
78	Statistical issues in drug development. <i>Statistical Methods in Medical Research</i> , 2011, 20, 577-578.	0.7	1
79	Investigating variability in patient response to treatment – a case study from a replicate cross-over study. <i>Statistical Methods in Medical Research</i> , 2011, 20, 657-666.	0.7	46
80	Measurement in clinical trials: A neglected issue for statisticians?. <i>Statistics in Medicine</i> , 2009, 28, 3189-3209.	0.8	115
81	Authors' Rejoinder to Commentaries on "Measurement in clinical trials: A neglected issue for statisticians?". <i>Statistics in Medicine</i> , 2009, 28, 3223-3225.	0.8	0
82	Issues with using baseline in last observation carried forward analysis. <i>Pharmaceutical Statistics</i> , 2008, 7, 142-146.	0.7	11
83	How Biased Are Indirect Comparisons, Particularly When Comparisons Are Made Over Time in Controlled Trials?. <i>Drug Information Journal</i> , 2008, 42, 625-633.	0.5	28
84	Are hospital league tables calculated correctly?. <i>Public Health</i> , 2007, 121, 902-904.	1.4	11
85	Increases in asthma hospital admissions associated with the end of the summer vacation for school-age children with asthma in two cities from England and Scotland. <i>Public Health</i> , 2007, 121, 482-484.	1.4	27
86	Predicting where future means will lie based on the results of the current trial. <i>Contemporary Clinical Trials</i> , 2007, 28, 352-357.	0.8	12
87	Literature review October-December 2006. <i>Pharmaceutical Statistics</i> , 2007, 6, 67-68.	0.7	0
88	A personal perspective on the Royal Statistical Society report of the working party on statistical issues in first-in-man studies. <i>Pharmaceutical Statistics</i> , 2007, 6, 75-78.	0.7	10
89	Are we getting what we pay for?. <i>Public Health</i> , 2006, 120, 1013-1019.	1.4	1
90	Sample size calculations for clinical studies allowing for uncertainty about the variance. <i>Pharmaceutical Statistics</i> , 2006, 5, 29-37.	0.7	52

#	ARTICLE	IF	CITATIONS
91	Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. <i>Pharmaceutical Statistics</i> , 2005, 4, 37-46.	0.7	38
92	Why do we use pooled variance analysis of variance?. <i>Pharmaceutical Statistics</i> , 2005, 4, 3-5.	0.7	15
93	Sample size of 12 per group rule of thumb for a pilot study. <i>Pharmaceutical Statistics</i> , 2005, 4, 287-291.	0.7	1,632
94	Issues with number needed to treat. <i>Statistics in Medicine</i> , 2005, 24, 3233-3235.	0.8	18
95	Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe, <i>Statistics in Medicine</i> 1998;17:857-872. <i>Statistics in Medicine</i> , 2005, 24, 3383-3384.	0.8	71
96	Letter to the Editors. <i>Biometrics</i> , 2004, 60, 284-284.	0.8	6
97	Sample sizes for clinical trials with Normal data. <i>Statistics in Medicine</i> , 2004, 23, 1921-1986.	0.8	451
98	Sample sizes for estimation in clinical research. <i>Pharmaceutical Statistics</i> , 2004, 3, 213-215.	0.7	27
99	Using confidence intervals around individual means to assess statistical significance between two means. <i>Pharmaceutical Statistics</i> , 2004, 3, 217-222.	0.7	176
100	Designing clinical trials with uncertain estimates of variability. <i>Pharmaceutical Statistics</i> , 2004, 3, 261-268.	0.7	18
101	The ABC of pharmaceutical trial design: some basic principles. <i>Pharmaceutical Statistics</i> , 2002, 1, 45-53.	0.7	7
102	Atmospheric pressure and sudden infant death syndrome in Cook County, Chicago. <i>Paediatric and Perinatal Epidemiology</i> , 2001, 15, 287-289.	0.8	10
103	Problems with the performance of the SF-36 among people with type 2 diabetes in general practice. <i>Quality of Life Research</i> , 2001, 10, 661-670.	1.5	63
104	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design by L. Frison and S.J. Pocock, <i>Statistics in Medicine</i> 1992; 12: 1685-1704. <i>Statistics in Medicine</i> , 2000, 19, 3133-3135.	0.8	3
105	WHY ARE PHARMACOKINETIC DATA SUMMARIZED BY ARITHMETIC MEANS?. <i>Journal of Biopharmaceutical Statistics</i> , 2000, 10, 55-71.	0.4	90
106	LETTER TO THE EDITOR: SAMPLE SIZES CALCULATIONS FOR ORDERED CATEGORICAL DATA by J. Whitehead, <i>Statistics in Medicine</i> , 12, 2257-2272 (1993).. , 1996, 15, 1065-1066.		8
107	LETTER TO THE EDITOR: SAMPLE SIZES CALCULATIONS FOR ORDERED CATEGORICAL DATA by J. Whitehead, <i>Statistics in Medicine</i> , 12, 2257-2272 (1993).. <i>Statistics in Medicine</i> , 1996, 15, 1065-1066.	0.8	1
108	A postal survey of the quality of long-term institutional care. <i>International Journal of Geriatric Psychiatry</i> , 1994, 9, 619-625.	1.3	8

#	ARTICLE	IF	CITATIONS
109	Confounding and Simpson's paradox. BMJ: British Medical Journal, 1994, 309, 1480-1481.	2.4	132
110	Sample Sizes for Clinical Trials. , 0, , .		98